Christopher J Jemapete insider trades: Gene Biotherapeutics (CRXM) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 17, 2021 | CRXM | ↑ Buy | 500,000 | $0.18 | $92K | Direct | Mar 18, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Christopher J Jemapete's insider trades
Christopher J Jemapete is a 10% owner of Gene Biotherapeutics (CRXM). Since Mar 17, 2021, Christopher has reported 1 open-market purchase worth $92K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRXM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.